Clinical Trial Update: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

View source ↗

Summary

Clinical trial update on the long-term safety follow-up of WU-CART-007 showing the study is currently enrolling by invitation for patients with T-cell acute lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• WU-CART-007

Snippet

Sponsor: Wugen, Inc. | Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma | Status: ENROLLING_BY_INVITATION